Laffer Tengler Investments Inc. Trims Stock Position in Johnson & Johnson $JNJ

Laffer Tengler Investments Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 13.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 43,400 shares of the company’s stock after selling 7,015 shares during the quarter. Johnson & Johnson makes up about 1.3% of Laffer Tengler Investments Inc.’s holdings, making the stock its 25th largest position. Laffer Tengler Investments Inc.’s holdings in Johnson & Johnson were worth $8,047,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Norges Bank acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $4,877,174,000. Laurel Wealth Advisors LLC raised its position in Johnson & Johnson by 15,040.6% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock valued at $1,133,512,000 after purchasing an additional 7,371,687 shares during the last quarter. Vanguard Group Inc. boosted its stake in Johnson & Johnson by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after purchasing an additional 3,085,180 shares during the period. Geode Capital Management LLC increased its stake in Johnson & Johnson by 2.1% in the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after purchasing an additional 1,225,676 shares during the period. Finally, Legal & General Group Plc raised its holdings in shares of Johnson & Johnson by 6.2% in the second quarter. Legal & General Group Plc now owns 18,917,274 shares of the company’s stock valued at $2,889,614,000 after buying an additional 1,097,855 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 0.7%

Shares of JNJ stock opened at $246.77 on Wednesday. The business’s fifty day moving average price is $226.32 and its 200 day moving average price is $203.01. The firm has a market capitalization of $594.69 billion, a PE ratio of 22.33, a P/E/G ratio of 2.41 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $251.71.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion for the quarter. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA Fast Track for nipocalimab in systemic lupus erythematosus (SLE) — designation follows positive Phase 2 data and a Phase 3 enrollment; this can speed review and raises the commercial potential of a new immunology asset. PR Newswire
• Positive Sentiment: Drug pipeline momentum: J&J reported encouraging early results for oncology candidate pasritamig and is preparing Phase 3 plans; continued progress across immunology and neuroscience (Tremfya, Caplyta, Spravato) is offsetting some revenue headwinds. Yahoo Finance
• Positive Sentiment: Market context: broader Dow strength is supporting JNJ’s move higher today as large-cap pharma recovers, giving momentum to shares. Kalkine Media
• Neutral Sentiment: Investor events and cadence: J&J scheduled an investor conference call for April 14 to review Q1 results — a routine event that could provide guidance/clarity but is not immediate catalyst. Business Wire
• Neutral Sentiment: Income appeal: J&J appears on several March dividend-stock lists, reinforcing steady-income investor interest but offering limited short-term price impact. Blockonomi
• Neutral Sentiment: Conference presentation material (TD Cowen transcript) gives investors detail on strategy and pipeline execution; useful for longer-term thesis but not an immediate mover. Seeking Alpha
• Negative Sentiment: Bayer legal action: Bayer has initiated a legal challenge related to prostate-cancer product claims — this creates regulatory and litigation risk that could weigh on sentiment and add to uncertainty. Yahoo Finance
• Negative Sentiment: Analyst stance: some sell-side notes (Bank of America reiteration/Hold) point to limited near-term upside despite better oncology estimates — tempers rally expectations. TipRanks

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 1,322 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,251,310.02. The trade was a 4.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 30,142 shares of company stock valued at $7,360,528. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of a number of research reports. Morgan Stanley set a $262.00 price target on Johnson & Johnson and gave the stock an “overweight” rating in a report on Wednesday, January 28th. Rothschild & Co Redburn lifted their target price on Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research note on Thursday, February 19th. TD Cowen upped their price target on Johnson & Johnson from $222.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Daiwa Securities Group upped their price objective on shares of Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research report on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $232.70.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.